HIV Therapy - What Do We Know, and When Do We Know It?

New England Journal of Medicine

Volumn 349, Issue 24, 2003, Pages 2351-2352

  Skolnik, Paul R ^a  

^a BOSTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; VIRUS RNA; ZIDOVUDINE;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DATA ANALYSIS; DRUG CHOICE; DRUG EFFECT; DRUG EFFICACY; EDITORIAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT FAILURE;

ANTI-RETROVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; RESEARCH DESIGN;

EID: 0345529114     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMe038173     Document Type: Editorial

References (8)

1. Robbins GK, De Gruttola V, Shafer RW, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003;349:2293-303.
2. Shafer RW, Smeaton LM, Robbins GR, et al. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003;349:2304-15.
3. Gallant JE, Rodriquez AE, Weinberg W, et al. Early nonresponse to tenofovir DF (TDF) + abacavir (ABC) and lamivudine (3TC) in a randomized trial compared to efavirenz (EFV) + ABC and 3TC: ESS30009 unplanned interim analysis. Presented at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, September 14-17, 2003. abstract.
4. Toole J. High rate of virologic failure in patients with HIV infection treated with a once-daily triple NRTI regimen containing didanosine, lamivudine, and tenofovir (important drug warning letter). Foster City, Calif.: Gilead, October 14, 2003.
5. Panel on Clinical Practices for Treatment of HIV Infection, Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents: November 10, 2003. (Accessed November 18, 2003, at http://aidsinfo.nih.gov.)
6. Palella FJ Jr, Deloria-Knoll M, Chmiel JS, et al. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann Intern Med 2003;138:620-6.
7. Lane HC, Neaton JD. When to start therapy for HIV infection: a swinging pendulum in search of data. Ann Intern Med 2003;138:680-1.
8. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study: Swiss HIV Cohort Study. Lancet 1999;353:863-8.